IART · US market
Integra LifeSciences Holdings Corp
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$1.25bnFinancials dated 30 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- -US$7.24m
- Latest-quarter run-rate earnings
- US$17.93m
- Latest fiscal-year earnings
- -US$516.47m
- Trailing revenue
- US$1.65bn
- Latest-quarter run-rate revenue
- US$1.68bn
- Latest fiscal-year revenue
- US$1.64bn
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- PVIVX · Paradigm Micro-Cap Fund3.92% weight · Holdings dated 30 June 2026
- PVFAX · Paradigm Value Fund2.60% weight · Holdings dated 30 June 2026
- XHE · State Street SPDR S&P Health Care Equipment ETF1.15% weight · Holdings dated 19 August 2026
- IBRN · iShares Neuroscience and Healthcare ETF1.10% weight · Holdings dated 21 August 2026
- NSCFX · Nuveen Small-Cap Value Opportunities Fund Class R60.61% weight · Holdings dated 30 June 2026
- QQQS · Invesco NASDAQ Future Gen 200 ETF0.57% weight · Holdings dated 31 May 2026
- PSCH · Invesco S&P SmallCap Health Care ETF0.57% weight · Holdings dated 31 May 2026
- UBVVX · Undiscovered Managers Behavioral Value Fund Class R50.56% weight · Holdings dated 30 June 2026
- VSFAX · Federated Hermes MDT Small Cap Value Fund Class A0.47% weight · Holdings dated 30 June 2026
- TVOIX · Touchstone Small Cap Value Fund Institutional Class0.41% weight · Holdings dated 30 June 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 30 June 2026. Informational research, not investment advice.